Beta Bionics (NASDAQ:BBNX) Announces Earnings Results, Beats Estimates By $0.09 EPS

Beta Bionics (NASDAQ:BBNX) announced its quarterly earnings data on Wednesday. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09, FiscalAI reports. Beta Bionics had a negative return on equity of 25.65% and a negative net margin of 61.31%.The company had revenue of $32.01 million for the quarter.

Here are the key takeaways from Beta Bionics’ conference call:

• Q2 revenue increased 38% year over year to $32 million, driven by new patient starts and recurring pharmacy-supply revenue, while gross margin expanded 524 basis points to 59%.
• Management reiterated 2026 revenue guidance of $131 million–$136 million and raised its full-year gross-margin outlook to 58.5%–59.5%, citing pharmacy growth and manufacturing scale.
• The company expects new sales territories added in the first half to support stronger patient-start growth in the second half, with Q3 expected to exceed Q2 and seasonally stronger Q4 performance.
• Beta Bionics is targeting a full commercial launch of the Mint patch pump by the end of Q2 2027, has begun operating a semi-automated clean-room production line, and initiated a pivotal trial to expand iLet use to adults with Type 2 diabetes around mid-2027, subject to FDA clearance.
• The bi-hormonal system requires additional work on glucagon formulation and dosing algorithms, delaying further Phase IIa trials by less than a year; the company also continues remediation of an FDA warning letter focused on complaints handling and post-market surveillance.

Beta Bionics Trading Down 5.9%

Shares of BBNX traded down $0.84 during trading hours on Friday, hitting $13.43. The company had a trading volume of 177,658 shares, compared to its average volume of 1,128,431. The company has a market capitalization of $598.60 million, a PE ratio of -8.17 and a beta of 3.04. Beta Bionics has a one year low of $8.80 and a one year high of $32.71. The company’s fifty day moving average price is $14.97 and its two-hundred day moving average price is $13.22.

Wall Street Analysts Forecast Growth

BBNX has been the subject of a number of recent analyst reports. Truist Financial boosted their target price on shares of Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Beta Bionics in a research note on Friday, July 17th. The Goldman Sachs Group lifted their price objective on shares of Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Stifel Nicolaus dropped their target price on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Finally, Leerink Partners reduced their target price on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 22nd. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $20.10.

Insider Activity at Beta Bionics

In other Beta Bionics news, CFO Stephen Feider sold 4,896 shares of Beta Bionics stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $17.03, for a total value of $83,378.88. Following the transaction, the chief financial officer owned 165,931 shares in the company, valued at $2,825,804.93. The trade was a 2.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Jon Russell sold 4,222 shares of Beta Bionics stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total value of $53,239.42. Following the completion of the transaction, the insider owned 173,849 shares in the company, valued at $2,192,235.89. This trade represents a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 40,351 shares of company stock valued at $553,961 over the last 90 days. Company insiders own 5.30% of the company’s stock.

Institutional Trading of Beta Bionics

A number of institutional investors have recently modified their holdings of the company. Summit Securities Group LLC purchased a new stake in Beta Bionics during the fourth quarter valued at approximately $52,000. Caitong International Asset Management Co. Ltd boosted its stake in Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after acquiring an additional 1,818 shares in the last quarter. Strs Ohio purchased a new position in Beta Bionics in the first quarter worth $29,000. Legal & General Group Plc grew its holdings in Beta Bionics by 197.4% in the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock worth $58,000 after purchasing an additional 2,639 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its position in shares of Beta Bionics by 630,000.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 6,301 shares of the company’s stock worth $192,000 after purchasing an additional 6,300 shares in the last quarter.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.